miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells

Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative neoplasm characterized by the uncontrolled proliferation of myeloid cells. Primarily, BCR-ABL1 acts as a constitutively active tyrosine kinase that alters cell proliferation, differentiation, survival, and genetic stability in hematopoietic cells in which it is expressed [1,2].

Source: Experimental Hematology - December 16, 2022 Category: Hematology Authors: Yutthana Rittavee, J érôme Artus, Christophe Desterke, Isidora Simanic, Lucas Eduardo Botelho de Souza, Sandra Riccaldi, Sabrina Coignard, Yousef Ijjeh, Patricia Hugues, Annelise Bennaceur-Griscelli, Ali G. Turhan, Adlen Foudi Tags: Article Source Type: research